Brokerages Expect Aeglea Bio Therapeutics Inc (AGLE) to Announce -$0.50 Earnings Per Share

Wall Street brokerages predict that Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) will report ($0.50) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Aeglea Bio Therapeutics’ earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.58). Aeglea Bio Therapeutics reported earnings per share of ($0.49) during the same quarter last year, which suggests a negative year-over-year growth rate of 2%. The business is expected to issue its next quarterly earnings results on Tuesday, May 14th.

On average, analysts expect that Aeglea Bio Therapeutics will report full year earnings of ($2.12) per share for the current fiscal year, with EPS estimates ranging from ($2.53) to ($1.70). For the next year, analysts anticipate that the company will report earnings of ($1.77) per share, with EPS estimates ranging from ($2.21) to ($1.33). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Aeglea Bio Therapeutics.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.27). Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 71.39%.

A number of analysts recently weighed in on the stock. ValuEngine raised shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 5th. Zacks Investment Research raised shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a research note on Thursday, January 3rd. Finally, JPMorgan Chase & Co. assumed coverage on shares of Aeglea Bio Therapeutics in a research note on Thursday, March 21st. They issued an “overweight” rating and a $14.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Aeglea Bio Therapeutics currently has an average rating of “Buy” and an average target price of $20.20.

Aeglea Bio Therapeutics stock traded up $0.10 on Friday, reaching $8.05. 499,413 shares of the stock were exchanged, compared to its average volume of 210,698. The firm has a market cap of $229.12 million, a price-to-earnings ratio of -3.78 and a beta of 1.07. Aeglea Bio Therapeutics has a twelve month low of $6.31 and a twelve month high of $12.00.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Canada Pension Plan Investment Board bought a new position in shares of Aeglea Bio Therapeutics in the fourth quarter worth approximately $37,000. Meeder Asset Management Inc. grew its stake in shares of Aeglea Bio Therapeutics by 44.9% during the 4th quarter. Meeder Asset Management Inc. now owns 5,116 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,585 shares during the period. Bank of America Corp DE grew its stake in shares of Aeglea Bio Therapeutics by 299.9% during the 4th quarter. Bank of America Corp DE now owns 17,145 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 12,858 shares during the period. Millennium Management LLC bought a new stake in shares of Aeglea Bio Therapeutics during the 4th quarter valued at about $156,000. Finally, Rhumbline Advisers grew its stake in shares of Aeglea Bio Therapeutics by 48.7% during the 4th quarter. Rhumbline Advisers now owns 21,571 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 7,069 shares during the period. 56.89% of the stock is currently owned by hedge funds and other institutional investors.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Further Reading: Should you buy a closed-end mutual fund?

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.